Telix Pharmaceuticals Limited (ASX:TLX)
13.28
-0.11 (-0.82%)
Nov 17, 2026, 11:29 AM AEDT
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $477.35M USD in the half year ending June 30, 2026, with 99.22% growth. This brings the company's total for the last twelve months to $890.79M, up 167.52% year-over-year. In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth. That makes Telix Pharmaceuticals the 8,264th largest company in the world by revenue and 138th in Australia.
Revenue (ttm)
$890.79M
Revenue Growth
+167.52%
P/S Ratio
3.53
Revenue / Employee
$752.35K
Employees
1,184
Market Cap
4.51B AUD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Telix Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Dec 31, 2023 | 332.98M | 224.03M | 205.64% |
| Dec 31, 2022 | 108.95M | 103.42M | 1,873.24% |
| Dec 31, 2021 | 5.52M | 1.51M | 37.53% |
| Dec 31, 2020 | 4.01M | 1.57M | 64.21% |
| Dec 31, 2019 | 2.44M | 2.31M | 1,680.88% |
| Dec 31, 2018 | 137.28K | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 22.83B |
| Mesoblast | 173.82M |
| Clinuvel Pharmaceuticals | 94.02M |
| BLS Pharmaceuticals | 73.91M |
| Neuren Pharmaceuticals | 69.53M |
| PYC Therapeutics | 25.99M |
| Actinogen Medical | 12.67M |
| Starpharma Holdings | 12.67M |
Telix Pharmaceuticals News
- 11 days ago - Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth - GlobeNewsWire
- 11 days ago - Telix Targets $1.5 Bln Revenue In 2027 As ITM Deal May Accelerate Therapy Launch To 2027 - Nasdaq
- 12 days ago - Telix Pharmaceuticals Targets $1.5B Revenue as ITM Deal Speeds Therapy Push - MarketBeat
- 12 days ago - Telix Pharmaceuticals Shares Rebound After October Selloff With Pixclara Launch and ITM Deal in Focus - International Business Times (Australia)
- 13 days ago - Telix Pharmaceuticals Transcript: CMD 2026 - Transcripts
- 13 days ago - Telix Pharmaceuticals Slides: FY 2026 - Filings
- 26 days ago - Telix Pharmaceuticals falls -9.9% - TheFly
- 26 days ago - Telix Shares Sink Nearly 10% as Investors Shrug Off 19% Revenue Growth and Pixclara Launch in Third Quarter - International Business Times (Australia)